TABLE 2.

Other papillomavirus L2 expression constructs used in this study

Virus	L2 amino acids incor- porated	NCBI reference no.a	Primer sequence (5′ to 3′)b
			Forward	Reverse
HPV6b	314-459	NC_001355	AATTCCGGATCCGGGGCCCGCATTCATTATTTTTA	AATTCCGCGGCCGCCTAGGCCGCCACATCTG
HPV16	321-473	NC_001526	AATTCCGGATCCGGTGCTAAGGTACATTATTATTA	AATTCCGCGGCCGCCTAGGCAGCCAAAGAGAC
HPV33	319-467	NC_001528	AATTCCGGATCCGGAGCTAGAATACATTATTATC	AATTCCGCGGCCGCCTAGGCCGCCACACGGAC
HPV1a	347-507	NC_001356	AATTCCGGATCCGGGCCACAAAGCCATTTTTAC	AATTCCGCGGCCGCTTAAAAAAAAAAATGTTTGCG
HPV5	376-518c	NC_001531	AATCCGGATCCGGGTCGCAAGTCCATTTTTAC	AATTCCGCGGCCGCTCACAAATATTTTCTT
HPV12	360-518	NC_001577	AATTCCGGATCCGGATCACAGGTTCATTTTTATAG	AATTCCGCGGCCGCTCACAAATATTTTCTT
COPV1	360-513	NC_001619	AATTCCGGATCCGGGCCACAAAGCCATTTTTAC	AATTCCGCGGCCGCTTAAAAAAAAAAATGTTTGCG
BPV1	316-469	NC_001522	AATTCCGGATCCGGACCACAGCTACATGTCAGG	CTCGAGTTAGGCATGTTTCCGTTTTTTTCGTTTC

^aSequences are the same as those given in the NCBI reference with the exception of the HPV5 isolate. The relevant amino acid changes within the putative L1 binding domain of HPV5 are indicated on Fig. 5.

^bRestriction sites within the primer are underlined.

^cAlthough primers were designed such that HPV5 amino acids 360 to 518 would be incorporated, only amino acids 376 to 518 are present due to the presence of a cryptic BamHI site at position 5472 in the HPV5 isolate used for PCR amplification.